Biotechnology in the Heart of the Capital City

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries.

Find our more about our company

FYResults23

Full Year Results 2023

CSL reports 20% profit growth with a full-year net profit of $2.61 billion (1,2).

15 Aug 2023
Australian Minister for Skills and Training Bern

Minister for Skills and Training visits Bern

Australian Minister for Skills and Training visits CSL Behring in Bern and meets apprentices.

21 Jun 2023
Women in Digital Transformation Webinar

Digital transformation in the biopharma industry

Women in Digital: Learn more from CSL experts in the webinar on 9 June.

01 Jun 2023
YB Meisterpokal

Hopp YB!

We at CSL Behring AG in Bern are proud of our neighbor and partner BSC Young Boys.

05 May 2023
Nasri Nahas, Pierre-Jean Wipff (Biopôle), Adrian W. Zuercher (CSL)

New R&D office on the Biopôle campus in Lausanne

To strengthen its R&D foothold in the Romandy, CSL opens a permanent R&D office in one of the most thriving biotech hubs in S…

31 Mar 2023
Adrian Zuercher and the winner of the Biomedical Science Award 2023 Janine Fuhrer

CSL R&D Switzerland awards Biomedical Science Award

The three winners were honored at the graduation ceremony of the University of Bern. (Pictures: Adrian Moser)

28 Mar 2023
Wankdorf Visit: Raphael Wicky, Paul McKenzie, Livia Artuso and Wanja Greuel

Paul McKenzie visits Wankdorf Stadium

BSC Young Boys warmly welcomed Paul McKenzie, CSL's new CEO and Managing Director.

24 Mar 2023
Rare Disease Day 2023

Rare Disease Day 2023

On 28 February 2023 Rare Disease Day will be taking place. #seerare

24 Feb 2023
HY-EN

Half Year Results 2022/2023

CSL reported net income after tax of $1.62 billion in the first half of 2023.

14 Feb 2023
Load more